Merit Medical Systems, Inc.(MMSI) Stock Research - Grey Stern Research
Loading...

Merit Medical Systems, Inc. (MMSI) Stock Analysis

$103.27 (-0.41%)

MMSI Financial Performance


Use the table below to view Merit Medical Systems, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $103.27 -
52 Week Low $70.70 -
52 Week High $111.45 -
Market Cap $6.1 Billion 6/11
Gross Margin 49% 7/11
Profit Margin 8% 6/11
EBITDA margin 10% 7/11
Q3 - 2024 Revenue $355.2 Million 9/11
Q3 - 2024 Earnings $27.9 Million 6/11
Q3 - 2024 Free Cash Flow $0 Million 10/11
Trailing 4 Quarters Revenue $1.4 Billion 10/11
Trailing 4 Quarters Earnings $120.4 Million 6/11
Quarterly Earnings Growth 1% 7/11
Annual Earnings Growth 14% 5/11
Quarterly Revenue Growth 9% 3/11
Annual Revenue Growth 7% 4/11
Cash On Hand $376.7 Million 4/11
Short Term Debt $10.3 Million 8/11
Long Term Debt $799.8 Million 8/11

Merit Medical Systems, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Merit Medical Systems, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 50.48 2/11
PS 4.48 3/11
PB 4.40 3/11
PC 16.13 6/11
Liabilities to Equity 0.75 6/11
ROA 0.05 4/11
ROE 0.09 5/11
Current Ratio 2.33 6/11
Quick Ratio 0.36 4/11
Long Term Debt to Equity 0.58 4/11
Debt to Equity 0.59 4/11
Burn Rate 56.84 1/11
Cash to Cap 0.06 6/11
CCR 10/11
EV to EBITDA 178.02 1/11
EV to Revenue 4.80 4/11

Company Details

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate strictures; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.

CEO: Mr. Fred Lampropoulos

Website: https://www.merit.com

Address: 1600 W Merit Pkwy South Jordan, UTAH

Exchange: NASDAQ Global Select

Industry: Medical Instruments & Supplies

Merit Medical Systems, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Merit Medical Systems, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
DENTSPLY SIRONA Inc. XRAY $3.1 Billion
ResMed Inc. RMD $32.7 Billion
The Cooper Companies, Inc. COO $17.0 Billion
Haemonetics Corporation HAE $3.2 Billion
Teleflex Incorporated TFX $6.5 Billion
West Pharmaceutical Services, Inc. WST $16.3 Billion
AngioDynamics, Inc. ANGO $397.8 Million
ICU Medical, Inc. ICUI $3.5 Billion
AptarGroup, Inc. ATR $9.9 Billion
Envista Holdings Corporation NVST $3.1 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
MMSI Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 355.2 Million $27.9 Million
Q3 2024 $ 339.8 Million $28.4 Million
Q2 2024 $ 337.6 Million $35.7 Million
Q1 2024 $ 323.5 Million $28.2 Million
Q4 2023 $ 324.5 Million $27.6 Million
Q3 2023 $ 315.2 Million $25.8 Million
Q2 2023 $ 320.1 Million $20.2 Million
Q1 2023 $ 297.6 Million $20.7 Million

View All

MMSI Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $376.7 Million $2.4 Billion $810.1 Million $1.4 Billion
Q3 2024 $523.1 Million $2.4 Billion $750.5 Million $1.3 Billion
Q2 2024 $638.7 Million $2.4 Billion $871.1 Million $1.3 Billion
Q1 2024 $581.9 Million $2.3 Billion $872.7 Million $1.2 Billion
Q4 2023 $587.0 Million $2.3 Billion $905.2 Million $1.2 Billion
Q3 2023 $58.7 Million $1.8 Billion $355.3 Million $1.2 Billion
Q2 2023 $72.1 Million $1.8 Billion $407.1 Million $1.2 Billion
Q1 2023 $57.9 Million $1.7 Billion $266.5 Million $1.2 Billion

View All

MMSI Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $37.4 Million -$9.9 Million -$113.4 Million
Q2 2024 $57.2 Million -$11.3 Million $54.7 Million
Q1 2024 $23.7 Million -$12.5 Million -$5.2 Million
Q4 2023 $0 $0 $0
Q3 2023 $42.5 Million -$8.6 Million -$13.4 Million
Q2 2023 $11.8 Million -$5.5 Million $14.0 Million
Q1 2023 $1.8 Million -$12.8 Million -$432,000
Q4 2022 $15.5 Million -$12.5 Million $7.0 Million

View All